Philippe Aftimos, MD · @aftimosp · X·· 1 天前评分70
正文 · 机器翻译
🔹在FourLight-1 ph2试验中，CDK4选择性抑制剂Atirmociclib + fulvestrant在既往接受CDK4/6i后，较研究者选择方案改善了mPFS
🔹中性粒细胞减少是最常见的AE，并有1例与之相关的肺炎死亡
🔹下一步：在1L开展FourLight-3 ph3研究，与CDK4/6i对比
#ESMO26 #ESMOAmbassadors
166 浏览 · 1 赞 · 1 转发 · 1 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org帖内回复
- Philippe Aftimos, MD @aftimosp
Next steps: ❓Atirmociclib replacing CDK4/6i in triplets with ET and PIK3CAi? ❓Atirmociclib in the adjuvant setting? #ESMO26 #ESMOAmbassadors @myESMO
来源：Philippe Aftimos, MD · x.com